Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial

Matthay, 2012, The acute respiratory distress syndrome, J Clin Invest, 122, 2731, 10.1172/JCI60331 Thompson, 2017, Acute respiratory distress syndrome, N Engl J Med, 377, 562, 10.1056/NEJMra1608077 Bellani, 2016, Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries, JAMA, 315, 788, 10.1001/jama.2016.0291 Matthay, 2017, Concise review: mesenchymal stem (stromal) cells: biology and preclinical evidence for therapeutic potential for organ dysfunction following trauma or sepsis, Stem Cells, 35, 316, 10.1002/stem.2551 Walter, 2014, Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis, Lancet Respir Med, 2, 1016, 10.1016/S2213-2600(14)70217-6 Asmussen, 2014, Human mesenchymal stem cells reduce the severity of acute lung injury in a sheep model of bacterial pneumonia, Thorax, 69, 819, 10.1136/thoraxjnl-2013-204980 Lee, 2009, Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung, Proc Natl Acad Sci USA, 106, 16357, 10.1073/pnas.0907996106 Lee, 2013, Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria, Am J Respir Crit Care Med, 187, 751, 10.1164/rccm.201206-0990OC Laffey, 2017, Fifty years of research in ARDS. Cell-based therapy for acute respiratory distress syndrome. biology and potential therapeutic value, Am J Respir Crit Care Med, 196, 266, 10.1164/rccm.201701-0107CP Thille, 2013, Chronology of histological lesions in acute respiratory distress syndrome with diffuse alveolar damage: a prospective cohort study of clinical autopsies, Lancet Respir Med, 1, 395, 10.1016/S2213-2600(13)70053-5 Force, 2012, Acute respiratory distress syndrome: the Berlin Definition, JAMA, 307, 2526 Matthay, 2017, Clinical trials in acute respiratory distress syndrome: challenges and opportunities, Lancet Respir Med, 5, 524, 10.1016/S2213-2600(17)30188-1 Wilson, 2015, Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial, Lancet Respir Med, 3, 24, 10.1016/S2213-2600(14)70291-7 Liu, 2014, Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome, Ann Intensive Care, 4, 22, 10.1186/s13613-014-0022-z Rosenberg, 2002, Recent innovations in intensive care unit risk-prediction models, Curr Opin Crit Care, 8, 321, 10.1097/00075198-200208000-00009 Wiedemann, 2006, Comparison of two fluid-management strategies in acute lung injury, N Engl J Med, 354, 2564, 10.1056/NEJMoa062200 Seeley, 2008, Predictors of mortality in acute lung injury during the era of lung protective ventilation, Thorax, 63, 994, 10.1136/thx.2007.093658 Murray, 1988, An expanded definition of the adult respiratory distress syndrome, Am Rev Respir Dis, 138, 720, 10.1164/ajrccm/138.3.720 Bhandari, 2006, Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death, Nat Med, 12, 1286, 10.1038/nm1494 Parikh, 2017, Angiopoietins and Tie2 in vascular inflammation, Curr Opin Hematol, 24, 432, 10.1097/MOH.0000000000000361 Agrawal, 2013, Plasma angiopoietin-2 predicts the onset of acute lung injury in critically ill patients, Am J Respir Crit Care Med, 187, 736, 10.1164/rccm.201208-1460OC Calfee, 2012, Plasma angiopoietin-2 in clinical acute lung injury: prognostic and pathogenetic significance, Crit Care Med, 40, 1731, 10.1097/CCM.0b013e3182451c87 Zinter, 2016, Plasma angiopoietin-2 outperforms other markers of endothelial injury in prognosticating pediatric ARDS mortality, Am J Physiol Lung Cell Mol Physiol, 310, L224, 10.1152/ajplung.00336.2015 Gutbier, 2018, Prognostic and pathogenic role of angiopoietin-1 and -2 in pneumonia, Am J Respir Crit Care Med, 198, 220, 10.1164/rccm.201708-1733OC Kaplan, 2017, Impact of starting material (fresh versus cryopreserved marrow) on mesenchymal stem cell culture, Transfusion, 57, 2216, 10.1111/trf.14192 Galipeau, 2018, Mesenchymal stromal cells: clinical challenges and therapeutic opportunities, Cell Stem Cell, 22, 824, 10.1016/j.stem.2018.05.004 Pais, 2018, Influence of clinical factors and exclusion criteria on mortality in ards observational studies and randomized controlled trials, Respir Care, 63, 1060, 10.4187/respcare.06034 Brower, 1999, Prospective, randomized, controlled clinical trial comparing traditional versus reduced tidal volume ventilation in acute respiratory distress syndrome patients, Crit Care Med, 27, 1492, 10.1097/00003246-199908000-00015 Brower, 2000, Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome, N Engl J Med, 342, 1301, 10.1056/NEJM200005043421801 Rubenfeld, 2008, When is a negative phase II trial truly negative?, Am J Respir Crit Care Med, 178, 554, 10.1164/rccm.200807-1136ED